Status: current, Not sufficiently defined by necessary conditions definition status. Date: 27-Dec 2017. Module: SNOMED CT United Kingdom drug extension module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 105954901000001117 | Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose (product) | en | Fully specified name | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| 105955001000001117 | Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | en | Synonym | Active | Entire term case sensitive | SNOMED CT United Kingdom drug extension module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has excipient | Excipient not declared | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has NHS dm+d (dictionary of medicines and devices) controlled drug category | Controlled drug category No Controlled Drug Status | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has NHS dm+d (dictionary of medicines and devices) additional monitoring indicator | EMA (European Medicines Agency) monitoring | false | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator | NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Is a | Generic Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler 30 dose | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has AMP | Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has excipient | Lactose | false | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | VMP prescribing status (attribute) | Never valid to prescribe as a VMP | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | VMP non-availability indicator | Available | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has specific active ingredient | Fluticasone furoate | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has specific active ingredient | Vilanterol trifenatate | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has specific active ingredient | Umeclidinium bromide | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has dispensed dose form | Conventional release powder for inhalation | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Has NHS dm+d (dictionary of medicines and devices) basis of strength substance | Vilanterol | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Legal category | Prescription only medicine - legal category (qualifier value) | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Discontinued indicator | Never discontinued | true | Inferred relationship | Existential restriction modifier | ||
| Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose | Is a | Actual medicinal product pack | true | Inferred relationship | Existential restriction modifier |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR